Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosamprenavir Sodium Alginate
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : LGM Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
N-Zyme & LGM Pharma Develop World’s First Pepsin Inhibitor for Reflux Disease
Details : The collaboration aims to bring to market a first-in-class, pepsin inhibitor, fosamprenavir that is safe and effective for patients with LPR and/or persistent GERD symptoms.
Brand Name : NZYM-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 18, 2024
Lead Product(s) : Fosamprenavir Sodium Alginate
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : LGM Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?